VAXART INC

Vaxart’s oral flu vaccines target gut immunity, offering a painless, effective alternative to injections—an innovative biotech breakthrough with solid growth prospects.

Vaxart reports 12‑month safety data for its oral COVID‑19 vaccine, confirming no serious concerns and a well‑tolerated profile across 400 participants in a Phase 2b trial.

Vaxart’s breakthrough oral flu vaccine could reshape flu prevention, yet its biotech journey highlights high R&D costs, regulatory hurdles, and market volatility.

Vaxart’s oral flu vaccines harness gut immunity for safer, global vaccination, reshaping biotech with a digital-first, mucosal‑focused approach.

Vaxart’s oral flu vaccine uses gut‑immune stimulation for stronger protection, positioning the biotech firm as a game‑changer in needle‑free vaccination and a promising investment opportunity.

Vaxart’s new $25 million share‑sale plan with Lincoln Park Capital fuels its oral flu vaccine research, giving flexible capital while keeping full control over timing and quantity of stock.

Vaxart’s oral flu and norovirus vaccines spark biotech buzz, promising gut‑activated immunity and breakthrough data for lactating women and infants—watch its Nasdaq growth.

Vaxart’s oral flu vaccines spark gut‑immune responses, but the stock’s volatile performance and negative earnings highlight a speculative investment risk.

Vaxart’s pioneering oral flu vaccine tech sparks biotech buzz and investor interest—learn how gut‑stimulated immunity could reshape flu prevention and boost the company’s growth.

Vaxart’s oral flu vaccine tech sparks biotech buzz—despite volatile shares, its gut‑immune strategy and 3x book‑value valuation signal long‑term promise.